BrightStar Invests to Defeat Cancer
MILWAUKEE, September, 2022 – BrightStar Wisconsin Foundation today announced that it has invested in Milwaukee based Tundra Targeted Therapeutics, Inc., joining Golden Angels Investors in the funding round.
The company, originating as a spin-off from the Medical College of Wisconsin, has developed a platform that allows a patient’s own T-cells to more efficiently attack and destroy cancer cells. Once fully commercialized and available for human use, it would be more effective, limit toxicities, and lower treatment costs in about 30% of the types of cancer than other therapies now available.
“We have all been touched by cancer in some way, and the pain to families dealing with childhood cancer can be even more tragic,” said Todd Sobotka, BrightStar’s Executive Director. “We are proud that our investment can help to make this technology a reality and hope that near term results even exceed our expectations.”
Following the positive evidence shown thus far in the lab and in animal models, the company expects that additional proven results from the upcoming human safety and efficacy trials would position this technology to become the initial standard of care therapy for all relevant cancer treatments. The company will initially focus on CD30 positive pediatric cancers and is seeking patients to participate in studies beginning this fall. CD30 is commonly expressed on Hodgkin lymphoma, non-Hodgkin lymphoma, neuroblastoma, germ cell tumors, and leukemia.
For more information about Tundra Targeted Therapeutics, please reach out to firstname.lastname@example.org.